It is demonstrated that the Ahr-active omeprazole decreases invasion and metastasis in estrogen receptor (ER)-negative breast cancer cell lines by down-regulation of matrix metalloproteinase-9 (MMP-9) and C-X-C chemokine receptor 4 (CXCR4) [23]. Here, MMP9 is linked to breast carcinoma.